Breaking News

US Department of Labor, Loomis Armored US enter agreement resolving alleged race- and gender-based hiring discrimination at Houston facility CBP Officers Thwart Alleged Child Smuggling Attempt at the Hidalgo International Bridge Governor Abbott Deploys Additional State Resources To Assist Florida’s Hurricane Ian Recovery | Office of the Texas Governor FDA Roundup: October 4, 2022 Air Component Senior Leader Course influences culture of AF senior leaders, operational-level C2 > Air Force > Article Display Strengthening Alliances in the Pacific – U.S. and Japan Conduct 15th Information Technology Forum Governor Cooper Proclaims October Cybersecurity Awareness Month, Warns of Hurricane-Related Scams Holland America Line's Special 150th Anniversary Crossing is a Celebration of the Brand's Journey

As a result of the successful conclusion of the regulatory process and customary closing conditions, Nestlé today completed its acquisition of Valeant Pharmaceuticals International’s commercialisation rights to several key injectable aesthetic dermatology products in the US and Canada, as announced on 28 May 2014. These rights will be integrated into Nestlé Skin Health and commercialised by Galderma.

Based in Lausanne, Nestlé Skin Health is a global leader focused on enhancing the quality of life by delivering science-based solutions for the health of skin, hair and nails. Galderma, with approximately 5,000 employees and a presence in 80 countries, is the pharmaceutical arm of Nestlé Skin Health.

 


Contacts:

Media        Robin Tickle   Tel.: +41 21 924 22 00  
Investors                         Tel.: +41 21 924 35 09  

 

PDF press releases:

 

Galderma US press release:

Galderma finalizes major expansion in aesthetic and corrective dermatology in the US and Canada

Source link